Schizophrenia Clinical Trial
— TQTOfficial title:
A Double-Blind, Cross-Over Placebo-Controlled and Active-Controlled Trial To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia
Verified date | March 2024 |
Source | Merck Sharp & Dohme LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this study to evaluate the effect of a supratherapeutic dose of 80 mg MK-8189 on the QT interval corrected for heart rate (QTc interval) and to assess the safety and tolerability of multiple once-daily doses of MK-8189 in participants with schizophrenia. The primary hypothesis is that the administration of an 80 mg MK-8189 dose on Day 2 does not prolong the QTc interval to a clinically significant degree. Specifically, the true mean difference (MK-8189 - placebo) in QTc change from baseline is less than 10 milliseconds (msec).
Status | Completed |
Enrollment | 107 |
Est. completion date | February 22, 2024 |
Est. primary completion date | February 22, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Meets diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria. - Is in the non-acute phase of their illness. - Has a history of receiving and tolerating antipsychotics medication within the usual dose range employed for schizophrenia. - Participants with hypothyroidism, diabetes, high blood pressure, chronic respiratory conditions or other medical conditions could be considered if their condition is stable. Exclusion Criteria: - History of a primary DSM-5 axis I psychiatric diagnosis other than schizophrenia or schizoaffective disorder per the allowed DSM-5 criteria. - History of intellectual disability, borderline personality disorder, anxiety disorder, or organic brain syndrome. - History of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia (TD). - History of seizure disorder beyond childhood or is receiving treatment with any anticonvulsant to prevent seizures. - History of cancer. - History or presence of sick sinus syndrome, atrioventricular (AV) block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QTc interval, or conduction abnormalities. - History of risk factors for Torsades de Pointes (e.g., heart failure/cardiomyopathy or family history of long QT syndrome). - History of frequent syncope, vasovagal episodes, or epileptic seizures. - Family history of sudden cardiac death. - Has a positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV). - Had major surgery, donated, or lost 1 unit of blood within 4 weeks prior to the pre-study visit. |
Country | Name | City | State |
---|---|---|---|
United States | California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0003) | Glendale | California |
United States | Velocity Clinical Research, Hallandale Beach ( Site 0002) | Hallandale Beach | Florida |
United States | Hassman Research Institute Marlton Site ( Site 0001) | Marlton | New Jersey |
United States | NRC Research Institute ( Site 0004) | Orange | California |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in QT interval corrected for heart rate (QTc) following MK-8189 treatment | Electrocardiogram data will be obtained using a digital Holter device and the Fridericia correction of the QT interval (QTcF) will be determined. The change from baseline in QTcF will be calculated by subtracting the QTcF value at the timepoint from the QTcF baseline value. | Baseline and up to 3 days | |
Primary | Number of participants with adverse events (AEs) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to ~30 days | |
Primary | Number of participants who discontinue study drug due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to ~16 days | |
Secondary | Change from baseline in QT interval corrected for heart rate (QTc) following moxifloxacin treatment | Electrocardiogram data will be obtained using a digital Holter device and the Fridericia correction of the QT interval (QTcF) will be determined. The change from baseline in QTcF wil be calculated by subtracting the QTcF value at the timepoint from the QTcF baseline value. | Baseline and up to 3 days | |
Secondary | Area Under the Plasma Concentration-Time curve From Time 0 to 24 hours (AUC0-24) of MK-8189 | AUC0-24 is defined as the area under concentration-time curve from 0 to 24 hours. Blood samples taken at pre-dose and up to 24 hours post-dose will be used to determine the AUC0-24 of MK-8189. | Day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 14 hours postdose; Day 2: Predose, 0.5, 1, 2, 3, 4, 8, 11, 14, 16, 24 hours postdose | |
Secondary | Area Under the Plasma Concentration-Time Curve from Time 0 to last quantifiable concentration (AUC0-last) of MK-8189 | AUC0-last is the area under the plasma concentration-time curve from time zero to time of last measurable concentration. Blood samples taken at pre-dose and at multiple timepoints post-dose will be used to determine the AUC0-last of MK-8189. | Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 14 hours postdose; Day 2: Predose, 0.5, 1, 2, 3, 4, 8, 11, 14, 16, 24, 36, 48, 72 hours postdose | |
Secondary | Maximum Concentration (Cmax) of MK-8189 | Cmax is defined as the maximum concentration of MK-8189 observed in plasma. Blood samples taken at pre-dose and at multiple timepoints post-dose will be used to determine the Cmax of MK-8189. | Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 14 hours postdose; Day 2: Predose, 0.5, 1, 2, 3, 4, 8, 11, 14, 16, 24, 36, 48, 72 hours postdose | |
Secondary | Concentration of MK-8189 at 24 Hours (C24) post-dose | C24 is defined as the concentration of MK-8189 observed in plasma at 24 hours. Blood samples taken at 24 hours post-dose will be used to determine the C24 of MK-8189. | 24 hours post-dose | |
Secondary | Time to maximum concentration (Tmax) of MK-8189 | Tmax is defined as the time to maximum concentration of MK-8189 observed in plasma. Blood samples taken at pre-dose and at multiple timepoints post-dose will be used to determine the Tmax of MK-8189. | Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 14 hours postdose; Day 2: Predose, 0.5, 1, 2, 3, 4, 8, 11, 14, 16, 24, 36, 48, 72 hours postdose | |
Secondary | Apparent Terminal Half-life (t1/2) of MK-8189 | t1/2 is defined as the time required to divide the plasma concentration of MK-8189 by half after reaching pseudo-equilibrium. Blood samples taken at pre-dose and at multiple timepoints post-dose will be used to determine the t1/2 of MK-8189. | Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 14 hours postdose; Day 2: Predose, 0.5, 1, 2, 3, 4, 8, 11, 14, 16, 24, 36, 48, 72 hours postdose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |